key: cord-0863915-o45sziw1
authors: Li, Chun; Ren, Linzhu
title: Recent progress on the diagnosis of 2019 Novel Coronavirus
date: 2020-05-31
journal: Transbound Emerg Dis
DOI: 10.1111/tbed.13620
sha: f10f2b1802373a9c4f54e4c0e6aaae3c2b916b76
doc_id: 863915
cord_uid: o45sziw1

Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has become a global pandemic. Therefore, convenient, timely and accurate detection of SARS‐CoV‐2 is urgently needed. Here, we review the types, characteristics and shortcomings of various detection methods, as well as perspectives for the SARS‐CoV‐2 diagnosis. Clinically, nucleic acid‐based methods are sensitive but prone to false‐positive. The antibody‐based method has slightly lower sensitivity but higher accuracy. Therefore, it is suggested to combine the two methods to improve the detection accuracy of COVID‐19.

The most widely used methods are nucleotide acid-based detection technology. As recommended by WHO, quantitative real-time RT-PCR (RT-qPCR) is one of the commonly used techniques for virus detection, which has high sensitivity, rapid detection, and other desirable characteristics.

In the past two months, many scientific teams and companies have successively developed methods to detect SARS-CoV-2 Chu et al., 2020; , but different methods have different detection efficiency and some produce more false negatives (Table 1) (Wang, 2020; Zhang & Li, 2020) . Therefore, improving the detection efficiency is one of the most important tasks at present. A one-step RT-qPCR targeting ORF1b or nucleocapsid (N) gene of SARS-CoV-2 can detect 10 copies/reaction of plasmid DNA or 2 × 10 −4 -2000 TCID 50 /reaction of RNA extracted from virus cultures (Chu et al., 2020) . However, this method was designed to react with SARS-CoV-2 and its closely related viruses, such as SARS coronavirus (Chu et al., 2020) , which may lead to false-positive reactions for SARS-CoV-2 identification. Furthermore, Chan and colleagues developed a novel RT-qPCR assay targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel) of SARS-CoV-2 and found that the limit of detection (LOD) of the assay was 1.8 TCID 50 /ml with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts, which has higher analytical sensitivity than the widely used RdRp-P2 assay in European laboratories . Notably, the COVID-19-RdRp/Hel assay did not cross-react with other human-origin coronaviruses and respiratory pathogens , which can be used to differentiate SARS-CoV-2 and other respiratory pathogens. Using RT-qPCR, Lin, Xiang, et al., (2020) and compared detection efficiency of RT-qPCR on throat swabs, nasal swabs and sputum specimens, and found that the positive rates of sputum specimens, nasal swabs and throat swabs were 74.4%-88.9%, 53.6%-73.3% and 44.2%, respectively. This suggests that samples collected from the lower respiratory tract increase the accuracy of diagnosis.

Another promising detection method based on nucleotide acid is the reverse transcription loop-mediated isothermal amplification (RT-LAMP) (Table 1) (Lamb, Bartolone, Ward, & Chancellor, 2020; Lucia, Federico, & Alejandra, 2020; Metsky, Freije, Kosoko-Thoroddsen, Sabeti, & Myhrvold, 2020; Mohamed, Haim, & Jinzhao, 2020; Yang, Dang, et al., 2020; Yu et al., 2020; Zhang, Odiwuor, et al., 2020) .

The RT-LAMP is performed in one step at 63°C isothermal conditions, and the results are obtained within 15-40 min, by targeting the ORF1ab, spike (S), envelope (E) or/and N gene of SARS-CoV-2 Lamb et al., 2020; Mohamed et al., 2020; Yan et al., 2020; Yang, Dang, et al., 2020; Yu et al., 2020; Zhang, Odiwuor, et al., 2020) . The assay can detect the virus in the throat and nasal swabs, with an LOD in the sample of about 5-10 RNA copies and 99%-100% agreement with the commercial RT-qPCR Yang, Dang, et al., 2020; Zhang, Odiwuor, et al., 2020) .

The RT-LAMP result can be evaluated using real-time turbidimeter, electrophoresis or fluorescent, which is faster and more convenient for clinical diagnosis of SARS-CoV-2. Moreover, to provide a rapid, highly sensitive molecular test for point-of-care, such as home, clinic and points of entry, a two-stage isothermal amplification (COVID-19 Penn-RAMP) based on recombinase polymerase amplification (RPA) at 38°C and LAMP at 63°C was developed by Mohamed and colleagues (Mohamed et al., 2020) . Both processes of the COVID-19

Penn-RAMP can be performed in a closed tube followed by either fluorescence or colorimetric detection, with 10-fold more sensitivity than COVID-19 LAMP and COVID-19 RT-qPCR (Mohamed et al., 2020) . Recent studies showed that an RT-LAMP targeting the N gene of SARS-CoV-2 can specifically detect viral RNAs of SARS-CoV-2 but has no cross-reactivity with related coronaviruses, such These results demonstrate that the RT-LAMP method has a wider application market for SARS-CoV-2 diagnosis due to its relatively simple operation and low technical requirements for operators.

Clustered regularly interspaced short palindromic repeats (CRISPR)based diagnostic platforms have also been developed for point-ofcare nucleic acid detection, such as SHERLOCK or DETECTR (Table 1 ) (Broughton et al., 2020; Kostyusheva et al., 2020; Lucia et al., 2020; Metsky et al., 2020; Zhang, Abudayyeh, & Gootenberg, 2020) .

The CRISPR-based nucleic acid detection platforms combine recombinase polymerase amplification with CRISPR-Cas enzymology for specific recognition of targeted DNA or RNA sequences (Kellner, Koob, Gootenberg, Abudayyeh, & Zhang, 2019; Myhrvold et al., 2018) . It can sensitively detect as low as 10 copies/μL for synthetic RNA or in vitro viral RNA transcripts. The results of the CRISPR-based methods can be analysed by fluorescent or lateral flow strip in <1 hr with a setup time of less than 15 min (Kellner et al., 2019) . It can be used in areas at greatest risk of transmitting SARS-CoV-2 infection, including airports, emergency departments and local community hospitals, particularly in low-resource countries (Broughton et al., 2020; Zhang, Abudayyeh, et al., 2020) .

Moreover, Broughton and colleagues compared the workflow of the DETECTR, SHERLOCK and the RT-qPCR recommended by CDC/ WHO for SARS-CoV-2 detection and found that the LOD of these methods is 70-300 copies/µl, 10-100 copies/µl or 3.16-10 copies/ µl input sample, respectively (Broughton et al., 2020) . The assays can be finished in 30, 60 and 120 min, respectively (Broughton et al., 2020) . These results suggest that RT-qPCR is more sensitive than the CRISPR-based assay, while the latter is more convenient and timesaving than RT-qPCR. However, due to the lack of clinical detection samples, the sensitivity and specificity of the CRISPRbased method needs further verification in the clinic.

Although nucleotide acid-based methods are the recommended methods by many groups and WHO, some experts have recently reported that the sensitivity of nucleic acid detection in SARS-CoV-2 is low, even as low as 42.10% (Cai et al., ; Jia et al., 2020; Li, Yi, et al., 2020; Wang, 2020; Zhang & Li, 2020) . In some cases of nucleotide acid-based detection, a positive result will appear after repeated negative tests. Nasopharyngeal or throat swabs are negative many times, but finally, positive results are detected in sputum specimens or respiratory lavage fluid samples (Li, Yi, et al., 2020; Wang, 2020; Zhang & Li, 2020) . Moreover, there are several limitations in nucleotide acid-based detections, such as long turnaround time, complex operation, expensive equipment and trained technicians (Cai et al., ; Li, Yi, et al., 2020) . Therefore, many experts suggest using specific antibody detection as a supplement for nucleic acid detection, 

because the antibody-based methods are relatively cheap, easy to operate and have low technical requirements (Table 1) .

To date, enzyme-linked immunosorbent assay (ELISA), colloidal gold immunochromatographic assay (GICA) and chemiluminescence-immunoassay (CLIA) are the most commonly used methods for detection of SARS-CoV-2. As reported, antibody-based methods targeting IgG and IgM induced by the recombinant N and S proteins of SARS-CoV-2 are consistent with the results obtained by nucleic acid-based assay (Cai et al., ; Jia et al., 2020; Li, Yi, et al., 2020; Lin, Liu, et al., 2020; Xiang, Yan, et al., 2020; Zhong et al., 2020) .

Furthermore, the receptor-binding domain (RBD) of the viral S protein showed a better antigenicity than that of the viral N protein for the diagnosis of SARA-CoV-2 infection . Moreover, a recent report showed that IgA level in patient serum is positively correlated with the severity of the COVID-19 , indicating that serum IgA can also be used as a biological marker for the COVID-19 identification.

The sensitivities of IgG and IgM-targeted methods were >71.4%

and >57.2%, or even up to 97.5% and 87.5%, respectively (Cai et al., ; Jia et al., 2020; Lin, Liu, et al., 2020; Xiang, Wang, et al., 2020; Xiang, Yan, et al., 2020) . It was reported that ELISA is superior to lateral flow immunoassay (LFIA) in specific detection and quantification of SARS-CoV-2 IgM and IgG, and is highly sensitive to IgG 10 days after symptoms appear (Adams et al., 2020) . Notably, the sensitivities of RBD-specific IgA, IgM and IgG were 98.6%, 96.8% and 96.8%, and the specificities of RBD-specific IgA, IgM and IgG were 98.1%, 92.3% and 99.8%, respectively . Recently, Lin et al.

found that serological CLIA based on the recombinant N protein of SARS-CoV-2 had a higher performance for diagnosis of COVID-19 than that of the commercial ELISA kit, with more reliable sensitivity and specificity of 82.28% and 97.5%, respectively . Therefore, antibody-based methods are also effective methods to detect COVID-19.

To improve the detection efficiency, several groups developed antibody-based methods for simultaneous detection of IgG and IgM Jia et al., 2020; Li, Yi, et al., 2020; Ma et al., 2020; Xiang, Yan, et al., 2020) and found that the sensitivity of test detecting IgM and IgG simultaneously was significantly higher than the nucleic acid, IgM or IgG single detection (Jia et al., 2020) . The sensitivities of ELISA and GICA for simultaneous detection of IgM and IgG antibodies were 87.3% and 82.4%, respectively, with 90.63%-100% specificity (Li, Yi, et al., 2020; Xiang, Yan, et al., 2020) . Besides, the IgA/IgG or IgA/IgM/IgG combination can provide improved diagnostic reliability compared to conventional IgM/IgG combinations .

Clinically, specific IgA and IgM against SARS-CoV-2 can be detected 7 days after virus infection or 3-4 days after symptoms appear, and specific IgG of the virus appears in 7-10 days after SARS-CoV-2 infection (Adams et al., 2020; Cai et al., ; Guo et al., 2020; Li, Yi, et al., 2020; Xiang, Wang, et al., 2020; Xiang, Yan, et al., 2020; Xiang, Yan, et al., 2020) . The median concentrations of IgA and IgM reached a peak of 8.84 and 7.25 μg/ml at 16-20 days after onset, respectively (Adams et al., 2020). IgG titres increased within 3 weeks after symptoms appeared and the median concentration reached a peak of 16.47 μg/ml in 21-25 days after onset and began to decrease at the 8th week, but remained above the detection threshold (Adams et al., 2020) . For patients of different stages, the sensitivities of GICA strips targeting viral IgM or IgG antibody were 11.1%, 92.9% and 96.8% for the nucleic acid confirmed cases of the early (1-7 days after onset), middle (8-14 days after onset) and late stage of the COVID-19 (over 15 days), respectively . These results suggest that antibody detection of SARS-

CoV-2 can be performed in the middle to later stages of COVID-19.

Generally, a clinical diagnosis can be finalized in as little as 5-15 min via antibody-based methods (especially by commonly used serological GICA strip), using different types of blood samples, such as fingerstick blood, serum and plasma of venous blood (Cai et al., ; Jia et al., 2020; Li, Yi, et al., 2020; Pan et al., 2020; Xiang, Yan, et al., 2020) . Therefore, combined with nucleic acid detection, the detection of virus-specific antibody can significantly reduce "false negatives" of SARS-CoV-2 infection at the clinical level.

It is worth noting that the nucleic acid-based methods need to extract nucleic acid in advance, which is a labour-intensive and timeconsuming operation and also has risks of affecting nucleic acid extraction, thus misleading the diagnosis (Zhao et al., ) . To overcome this problem, a virus RNA extraction method was developed based on poly (amino ester) and carboxyl-coated magnetic nanoparticles, which combines the lysis and binding steps into one step and can be directly incorporated into RT-qPCR or RT-LAMP .

The simplified method can purify viral RNA from multiple samples in 20 min (Zhao et al., ) .

Moreover, to obtain the virus effectively, it is usually necessary to collect respiratory tract samples, such as nasopharyngeal aspirates/swabs or throat swabs. As reported by Wu et 

In conclusion, nucleic acid-based methods are sensitive, but prone to false-positive. The sensitivity of the antibody-based method is slightly lower, but the accuracy is higher. Therefore, it is suggested that the two methods should be combined to improve the detection accuracy of COVID-19. Moreover, developing a risk-free sample preparation method for detection is one of the urgent tasks to be solved at present. Also, because a few recovered patients that have

been discharged from hospitals have tested positive in nucleic acid tests, it is still necessary to develop new sensitive and specific detection methods for the confirmation of virus-infected persons, carriers and recovered patients. At the same time, the establishment of a differentiation method between SARS-CoV-2 and other respiratory viruses is also urgently needed.

Notably, SARS-CoV-2 is a zoonotic virus, but the host spectrum of the virus is still controversial. As reported, the virus was detected not only in humans, but also in dogs, ferrets, domestic cats, tigers and lions (Gollakner & Capua, 2020; Shi et al., 2020) , while a survey by Deng et al. showed that dogs and cats remained serologically negative to SARS-CoV-2 .

However, sequence analysis of angiotensin-converting enzyme 2 (ACE2) receptor between humans and animals indicates a low species barrier for transmission of SARS-CoV-2 to farm animals , demonstrating the virus might infect other species, especially pets and farm animals, from humans and vice versa.

Therefore, it is also necessary to monitor SARS-CoV-2 infection in pets and domestic animals. 

The authors declare no conflict of interest.

No ethical approval was required as this is a review article with no original research data.

The data that support the findings of this study are available on request from the corresponding author.

Linzhu Ren https://orcid.org/0000-0002-1092-6435

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. medRxiv

An update on the epidemiological characteristics of novel coronavirus pneumonia(COVID-19)

Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerging Microbes & Infections

A protocol for rapid detection of the 2019 novel coronavirus SARS-CoV-2 using CRISPR diagnostics: SARS-CoV-2 DETECTR

A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of corona virus disease 2019 (COVID-19). medRxiv

Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Molecular diagnosis of a novel Coronavirus (2019-nCoV) causing an outbreak of pneumonia

Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals

Is COVID-19 the first pandemic that evolves into a panzootic? Veterinaria Italiana

Profiling early humoral response to diagnose novel Coronavirus disease (COVID-19)

RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2

Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection

SHERLOCK: Nucleic acid detection with CRISPR nucleases

CRISPR-Cas Systems for Diagnosing Infectious Diseases

Rapid detection of novel coronavirus (COVID-19) by reverse transcription-loop-mediated isothermal amplification

Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species. Infection

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)

Evaluations of serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak

An ultrasensitive, rapid, and portable coronavirus SARS-CoV-2 sequence detection method based on CRISPR-Cas12

COVID-19 diagnosis and study of serum SARS-CoV-2 specific IgA, IgM and IgG by a quantitative and sensitive immunoassay

CRISPR-based surveillance for COVID-19 using genomically-comprehensive machine learning design

A single and twostage, closed-tube, molecular test for the 2019 novel coronavirus (COVID-19) at home, clinic, and points of entry

Field-deployable viral diagnostics using CRISPR-Cas13

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infection

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives

Consistent detection of 2019 novel coronavirus in saliva

Analysis of low positive rate of nucleic acid detection method used for diagnosis of novel coronavirus pneumonia

Detection and analysis of nucleic acid in various biological samples of COVID-19 patients

Antibody detection and dynamic characteristics in patients with COVID-19

Evaluation of enzyme-linked immunoassay and colloidal gold-immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19)

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

Rapid Detection of SARS-CoV-2 Using Reverse transcription RT-LAMP method

Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Rapid colorimetric detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform: iLACO

A protocol for detection of COVID-19 using CRISPR diagnostics

Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia

The way to reduce the "false negative results" of 2019 novel coronavirus nucleic acid detection

Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP

A simple magnetic nanoparticles-based viral RNA extraction method for efficient detection of SARS-CoV-2. bioRxiv

Detection of serum IgM and IgG for COVID-19 diagnosis

Recent progress on the diagnosis of 2019 Novel Coronavirus